Delivery Order SPE2DB20D2014-SPE2DB25FC91D
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication used to treat benign prostatic hyperplasia. The contract is firm fixed price with a ceiling value of $10,078.41 and an ultimate completion date of August 15, 2025. This is a non-set-aside competitive award, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. The contract, awarded on August 18, 2025, carries a ceiling value of $2,029.15 with a firm fixed price structure and an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This was a competitively awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. The contract was awarded on August 12, 2025, under a firm fixed-price delivery order structure with a ceiling value of $1,601.60 and an ultimate completion date of August 13, 2025. This non-set-aside award was competitively procured and will be performed at AmerisourceBergen's headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. This competitive delivery order, valued at $2,750.29 with firm fixed pricing, was awarded on August 6, 2025, with an ultimate completion date of August 7, 2025. The contract includes no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $1,192.79 and a completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical will be supplied from the vendor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a contract ceiling value of $1,727.65. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by August 8, 2025. The award represents a routine pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg at a ceiling value of $3,011.99. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, representing a routine pharmaceutical procurement for federal medical supply needs. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg at a firm fixed price of $5,508.13. This contract was awarded competitively with no set-aside designation and carries an ultimate completion date of October 21, 2025. The pharmaceutical product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,668.43 to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a pharmaceutical product commonly used to treat benign prostatic hyperplasia. The award, issued on July 16, 2025, with an ultimate completion date of July 17, 2025, represents a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Tamsulosin HCL 0.4 mg capsules in a quantity of 1,000 units, with a ceiling value of $1,441.15. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC91DDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $24,171.55, is scheduled for completion by September 5, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical procurement requirements. This delivery order represents a child contract under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, supplying a comprehensive range of generic and brand-name medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare systems and other government health agencies worldwide. The company's extensive federal contract portfolio demonstrates its role as a primary supplier for the Defense Health Agency and other federal healthcare customers across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.2k | 9/4/25 |